

Baxter International Inc.
Key Product Line Sales
Period Ending March 31, 2003
(Unaudited)

(\$ in Millions)	Q1 2003	Q1 2002	% Growth
------------------	------------	------------	-------------

BioScience			
Recombinants	244	232	5%
Plasma Proteins ¹	229	238	(4%)
Antibody Therapy	67	76	(12%)
Transfusion Therapies ²	134	130	3%

Medication Delivery			
IV Therapies ³	248	223	11%
Drug Delivery	161	132	21%
Electronic Infusion Systems	151	151	0%
Anesthesia ⁴	199	121	64%

Renal			
PD Therapy	301	300	0%
HD Therapy	103	97	6%

¹ Includes plasma-derived hemophilia (FVII, FVIII, FIX and FEIBA), albumin, biosurgery and other plasma-based products.

² Formerly referred to as Fenwal.

³ Principally includes intravenous solutions and nutritional products.

⁴ Includes ESI Lederle.